Project Grant R01AR085553
Award Date
7/1/25
Completion Date
3/31/30
Dollars Obligated
$568K
Similar Awards
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under CFDA 93.846 Arthritis, Musculoskeletal and Skin Diseases Research will support research to investigate the role of DNA methylation in intervertebral disc degeneration and chronic low back pain. The $658,385 award will fund a 5-year project to: 1) Identify the DNA methylation and gene expression landscape in human intervertebral disc degeneration and discogenic low back pain, 2)...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $196,460.00 to the University of Pittsburgh to test a novel microphysiological system for studying neuro-immune interactions in osteoarthritis pain. The project aims to use this miniature knee joint system to understand the influence of synovial inflammatory molecules on innervating...
This Project Grant award of $624,004.07 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research to investigate the role of the transcription factor HIF-1 in regulating intervertebral disc function and metabolism. The key objectives are to delineate the mechanisms by which HIF-1 controls glucose availability and lactate/pyruvate metabolism in nucleus pulposus...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) worth $735,372 to Brigham & Women's Hospital Inc. on May 15, 2025. The project, titled "T Cell Expression of Inflammatory Chemokine Receptors," aims to identify transcription factors and cytokines that regulate the expression of chemokine receptors, such as CCR2, CCR5, and CXCR6, on T cells in inflamed...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $605,253 to The Trustees of the University of Pennsylvania to investigate the mechanical crosstalk between the intervertebral disc and adjacent facet joints during spinal degeneration and repair. The research aims to characterize the progression of facet osteoarthritis following disc...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $774,930.00 to the Regents of the University of Minnesota to develop and validate a mouse model of intervertebral disc degeneration-induced low back pain. The goal is to create a clinically representative preclinical model that can facilitate the discovery of novel non-addictive analgesics for the treatment of discogenic low...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $608,358 to investigate the role of the neuropeptide calcitonin gene-related peptide (CGRP) in bone healing and chronic pain following bone fractures. The research aims to test the hypothesis that CGRP signaling is beneficial for bone healing but contributes to nociceptive pain...
This federal Project Grant award, totaling $2,884,007.00, was provided by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), under the Drug Use and Addiction Research Programs (CFDA 93.279). The purpose of the award is to conduct research investigating mechanisms of intra- and inter-individual pain variability in patients with comorbid chronic low back pain (CLBP) and major depressive disorder (MDD). The research will generate...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $1,657,392.00 to the University of Pittsburgh to conduct research on repurposing FDA-approved drugs for the treatment of osteoarthritis (OA). The research aims to leverage high-throughput screening in human cell-derived microphysiological models to identify disease-modifying OA drugs...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $220,224 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to The Regents of the University of Colorado, operating as the University of Colorado, with a period of performance from July 4, 2024 to August 31, 2027. The funding will support the development of granular hydrogels for the controlled delivery of immunomodulatory and angiogenic extracellular vesicles to enhance...